Tian Tian, Fu Leiwen, Wang Bingyi, Zhou Xinyi, Lin Yi-Fan, Gao Yanxiao, Li Yuwei, Sun Yinghui, Dai Jianghong, Zou Huachun
School of Public Health, Xinjiang Medical University, Urumqi, Xinjiang, PR China.
School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, Guangdong, PR China.
Vaccine X. 2024 Sep 1;20:100551. doi: 10.1016/j.jvacx.2024.100551. eCollection 2024 Oct.
Clearance of human papillomavirus (HPV) among adolescent men who have sex with men (MSM) is not well studied. This study aimed to evaluate the clearance of HPV DNA and antibodies among adolescent MSM.
In our cohort study, we enrolled adolescent MSM in Melbourne between October 2010 and September 2013. At baseline, 3, 6, and 12 months, anal and penile swabs for HPV DNA and serum for HPV antibodies against genotypes 6, 11, 16, and 18, were collected. Definite clearance was defined as HPV DNA (same site) /antibodies for the same genotype undetected following a positive HPV DNA /antibodies test at baseline or month 3. Possible clearance was defined as HPV DNA (same site) /antibodies for the same genotype undetected at month 12 following a positive HPV DNA/antibodies test at month 6. Overall clearance was defined as either definite or possible clearance. The agreement between HPV DNA clearance and antibodies clearance was calculated.
A total of 183 MSM were included (median age: 19 years, interquartile [IQR]: 18 to 20). At the anus, overall clearance rate was 21.6 (95 % confidence interval[CI]: 7.9 to 47.0), 44.8 (19.3 to 88.3), 51.9 (20.9 to 106.9) and 33.7 (7.0 to 98.5) per 1000 person months (PM) for HPV 6, 11, 16 and 18. At the penis, overall clearance rate was 64.5 (13.3 to 188.5), 71.3 (14.7 to 208.2), 96.5 (31.3 to 225.3) and 333.3 (8.4 to 1857.2) per 1000 PM for HPV 6, 11, 16 and 18. For antibodies, overall clearance rate was 22.2 (9.6 to 43.7), 18.8 (3.9 to 55.0), 10.8 (0.3 to 60.1) and 19.0 (2.3 to 68.8) per 1000 PM. Agreement between anal/penile HPV DNA clearance and antibodies clearance was low: = -0.18 (95 % CI: -0.28 to 0.08)/-0.13 (-0.24 to -0.02), 0.04 (-0.29 to 0.36)/0.22 (-0.32 to 0.76), -0.10 (-0.27 to 0.08)/-0.14 (-0.37 to 0.10) and -0.14 (-0.28 to 0.01)/-0.14 (-0.33 to 0.06) for HPV 6, 11, 16 and 18, respectively.
Clearance rates of HPV DNA were low and varied by genotypes and anatomical sites among adolescent MSM. Antibodies against HPV were stable during the study period.
男男性行为者（MSM）中人类乳头瘤病毒（HPV）清除情况的研究较少。本研究旨在评估青少年男男性行为者中HPV DNA和抗体的清除情况。
在我们的队列研究中，2010年10月至2013年9月期间，我们招募了墨尔本的青少年男男性行为者。在基线、3个月、6个月和12个月时，采集肛门和阴茎拭子用于检测HPV DNA，采集血清用于检测针对6、11、16和18型HPV的抗体。明确清除定义为在基线或第3个月HPV DNA/抗体检测呈阳性后，未检测到相同基因型的HPV DNA（同一位点）/抗体。可能清除定义为在第6个月HPV DNA/抗体检测呈阳性后，第12个月未检测到相同基因型的HPV DNA（同一位点）/抗体。总体清除定义为明确清除或可能清除。计算HPV DNA清除和抗体清除之间的一致性。
共纳入183名男男性行为者（中位年龄：19岁，四分位间距[IQR]：18至20岁）。在肛门部位，HPV 6、11、16和18型的每1000人月（PM）总体清除率分别为21.6（95%置信区间[CI]：7.9至47.0）、44.8（19.3至88.3）、51.9（20.9至106.9）和33.7（7.0至98.5）。在阴茎部位，HPV 6、11、16和18型的每1000 PM总体清除率分别为64.5（13.3至188.5）、71.3（14.7至208.2）、96.5（31.3至225.3）和333.3（8.4至1857.2）。对于抗体，每1000 PM的总体清除率分别为22.2（9.6至43.7）、18.8（3.9至55.0）、10.8（0.3至60.1）和19.0（2.3至68.8）。肛门/阴茎HPV DNA清除和抗体清除之间的一致性较低：HPV 6、11、16和18型的一致性分别为=-0.18（95% CI：-0.28至0.08）/-0.13（-0.24至-0.02）、0.04（-0.29至0.36）/0.22（-0.32至0.76）、-0.10（-0.27至0.08）/-0.14（-0.37至0.10）和-0.14（-0.28至0.01）/-0.14（-0.33至0.06）。
青少年男男性行为者中HPV DNA的清除率较低，且因基因型和解剖部位而异。在研究期间，HPV抗体较为稳定。
